Literature DB >> 25614172

Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis.

Brett Ley1, Williamson Z Bradford2, Derek Weycker3, Eric Vittinghoff4, Roland M du Bois5, Harold R Collard6.   

Abstract

The Gender-Age-Physiology (GAP) model is a validated, baseline-risk prediction model for mortality in idiopathic pulmonary fibrosis. Longitudinal variables have been shown to contribute to risk prediction in idiopathic pulmonary fibrosis and may improve the predictive performance of the baseline GAP model. Our aims were to further validate the GAP model and evaluate whether the addition of longitudinal variables improves its predictive performance. The study population was derived from a large clinical trials cohort of patients with idiopathic pulmonary fibrosis (n=1109). Model performance was determined by improvement in the C-statistic, net reclassification improvement, clinical net reclassification improvement, and a goodness-of-fit test. The GAP model had good discriminative performance with a C-statistic of 0.757 (95% CI 0.750-0.764). However, the original GAP model tended to overestimate risk in this cohort. A novel, easy to use model, consisting of the original GAP predictors plus history of respiratory hospitalisation and 24-week change in forced vital capacity (the longitudinal GAP model) improved model performance with a C-statistic of 0.785 (95% CI 0.780-0.790), net reclassification improvement of 8.5%, clinical net reclassification improvement of 25%, and a goodness-of-fit test of 0.929. The Longitudinal GAP model, along with the original GAP model, may unify baseline and longitudinal mortality risk prediction in idiopathic pulmonary fibrosis.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25614172     DOI: 10.1183/09031936.00146314

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  23 in total

1.  Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.

Authors:  Marilyn K Glassberg; Julia Minkiewicz; Rebecca L Toonkel; Emmanuelle S Simonet; Gustavo A Rubio; Darcy DiFede; Shirin Shafazand; Aisha Khan; Marietsy V Pujol; Vincent F LaRussa; Lisa H Lancaster; Glenn D Rosen; Joel Fishman; Yolanda N Mageto; Adam Mendizabal; Joshua M Hare
Journal:  Chest       Date:  2016-11-24       Impact factor: 9.410

2.  The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.

Authors:  Deborah Assayag; Eric Vittinghoff; Christopher J Ryerson; Elisabetta Cocconcelli; Roberto Tonelli; Xiaowen Hu; Brett M Elicker; Jeffrey A Golden; Kirk D Jones; Talmadge E King; Laura L Koth; Joyce S Lee; Brett Ley; Anthony K Shum; Paul J Wolters; Jay H Ryu; Harold R Collard
Journal:  Respir Med       Date:  2015-06-24       Impact factor: 3.415

3.  Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.

Authors:  Margaret L Salisbury; Meng Xia; Yueren Zhou; Susan Murray; Nabihah Tayob; Kevin K Brown; Athol U Wells; Shelley L Schmidt; Fernando J Martinez; Kevin R Flaherty
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

4.  Will Adding Fibrotic Score to the GAP Score Help Predict Patient Survival?

Authors:  Jonathan H Chung
Journal:  Radiol Cardiothorac Imaging       Date:  2019-06-27

Review 5.  Recent advances in understanding idiopathic pulmonary fibrosis.

Authors:  Cécile Daccord; Toby M Maher
Journal:  F1000Res       Date:  2016-05-31

6.  Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Authors:  Thomas Bahmer; Anne-Marie Kirsten; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Marco Gramm; Simone Hummler; Eva Brunnemer; Michael Kreuter; Henrik Watz
Journal:  BMC Pulm Med       Date:  2017-07-25       Impact factor: 3.317

7.  CT-derived 3D-diaphragm motion in emphysema and IPF compared to normal subjects.

Authors:  Ji Hee Kang; Jiwoong Choi; Kum Ju Chae; Kyung Min Shin; Chang-Hoon Lee; Junfeng Guo; Ching-Long Lin; Eric A Hoffman; Changhyun Lee
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.996

8.  Models of disease behavior in idiopathic pulmonary fibrosis.

Authors:  Kerri A Johannson; Brett Ley; Harold R Collard
Journal:  BMC Med       Date:  2015-09-24       Impact factor: 8.775

9.  Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.

Authors:  Sang Hoon Lee; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Sung Woo Park; Moo Suk Park
Journal:  Respir Res       Date:  2016-10-18

10.  Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation.

Authors:  Jungnam Lee; Ivan Arisi; Ermanno Puxeddu; Lazarus K Mramba; Massimo Amicosante; Carmen M Swaisgood; Marco Pallante; Mark L Brantly; C Magnus Sköld; Cesare Saltini
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.